Equivir - GRDG Sciences
Latest Information Update: 28 Mar 2024
At a glance
- Originator GRDG Sciences
- Class Antivirals; Flavonoids; Phenols
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported COVID 2019 infections; Dengue; Ebola virus infections; Influenza A virus H1N1 subtype; Influenza A virus H3N2 subtype; Influenza A virus H5N1 subtype; Influenza A virus H7N9 subtype; Influenza B virus infections; Parainfluenza virus infections; Rhinovirus infections
Most Recent Events
- 28 Mar 2024 No recent reports of development identified for preclinical development in COVID-2019-infections in USA
- 28 Mar 2024 No recent reports of development identified for preclinical development in Dengue in USA
- 28 Mar 2024 No recent reports of development identified for preclinical development in Ebola-virus-infections in USA
Development Overview
Introduction
Equivir is a combination of myricetin, hesperidin and piperine phenolic flavonoid compounds, being developed by GRDG Sciences for the treatment of various viral infections including influenza (H1N1, H3N2, H5N1, H7N9, Influenza B, Parainfluenza 3), rhinovirus, ebola, dengue virus and coronavirus infection (COVID-2019-infections and Human Coronavirus-A). In preclinical studies, equivir showed enhanced antiviral properties in terms of efficacy in treating influenza, dengue virus and ebola. Preclinical development is underway in the US.
As at March 2024, no recent reports of development had been identified for preclinical development in COVID-2019-infections in USA, preclinical development in Dengue in USA, preclinical development in Ebola-virus-infections in USA, preclinical development in Influenza-A virus H3N2 subtype in USA, preclinical development in Influenza-A virus H7N9 subtype in USA, preclinical development in Influenza-A-virus-H1N1-subtype in USA, preclinical development in Influenza-A-virus-H5N1-subtype in USA, preclinical development in Influenza-B-virus-infections in USA, preclinical development in Parainfluenza-virus-infections in USA, preclinical development in Rhinovirus-infections in USA.
Key Development Milestones
As of February 2020, Equivir demonstrated in vitro efficacy against multiple strains of Influenza (H1N1, H3N2, H5N1, H7N9, Influenza B, Parainfluenza 3), Human Rhinovirus-14, Human Coronavirus-A, and Ebola. The company intends to conduct additional testing for the equivir for the treatment of COVID-2019 infections, the disease caused by the pandemic novel coronavirus SARS-CoV2 [1] .
Patent Information
As of February 2020, Global Biolife has a multiple patents pending worldwide for electrophilically enhanced phenolic compounds for treating inflammatory related diseases and disorders [2]
In November 2018, Global Biolife has patent US 10 123 991 B2 granted for electrophilically enhanced phenolic compounds for treating inflammatory related diseases and disorders in the US. The patent will expire in May 2036 [2] .
Drug Properties & Chemical Synopsis
- Formulation unspecified
- Class Antivirals, Flavonoids, Phenols
- Mechanism of Action Undefined mechanism
-
WHO ATC code
J05 (Antivirals for Systemic Use)
-
EPhMRA code
J5 (Antivirals for Systemic Use)
Development Status
Summary Table
| Indication | Qualifier | Patient Segment | Phase | Countries | Route / Formulation | Developers | Event Date |
|---|---|---|---|---|---|---|---|
| COVID 2019 infections | - | - | No development reported (Preclinical) | USA | unspecified / unspecified | GRDG Sciences | 28 Mar 2024 |
| Dengue | - | - | No development reported (Preclinical) | USA | unspecified / unspecified | GRDG Sciences | 28 Mar 2024 |
| Ebola virus infections | - | - | No development reported (Preclinical) | USA | unspecified / unspecified | GRDG Sciences | 28 Mar 2024 |
| Influenza A virus H1N1 subtype | - | - | No development reported (Preclinical) | USA | unspecified / unspecified | GRDG Sciences | 28 Mar 2024 |
| Influenza A virus H3N2 subtype | - | - | No development reported (Preclinical) | USA | unspecified / unspecified | GRDG Sciences | 28 Mar 2024 |
| Influenza A virus H5N1 subtype | - | - | No development reported (Preclinical) | USA | unspecified / unspecified | GRDG Sciences | 28 Mar 2024 |
| Influenza A virus H7N9 subtype | - | - | No development reported (Preclinical) | USA | unspecified / unspecified | GRDG Sciences | 28 Mar 2024 |
| Influenza B virus infections | - | - | No development reported (Preclinical) | USA | unspecified / unspecified | GRDG Sciences | 28 Mar 2024 |
| Parainfluenza virus infections | - | - | No development reported (Preclinical) | USA | unspecified / unspecified | GRDG Sciences | 28 Mar 2024 |
| Rhinovirus infections | - | - | No development reported (Preclinical) | USA | unspecified / unspecified | GRDG Sciences | 28 Mar 2024 |
Commercial Information
Involved Organisations
| Organisation | Involvement | Countries |
|---|---|---|
| GRDG Sciences | Originator | USA |
| GRDG Sciences | Owner | USA |
| Global BioLife. | Collaborator | USA |
Development History
| Event Date | Update Type | Comment |
|---|---|---|
| 28 Mar 2024 | Phase Change - No development reported | No recent reports of development identified for preclinical development in COVID-2019-infections in USA Updated 28 Mar 2024 |
| 28 Mar 2024 | Phase Change - No development reported | No recent reports of development identified for preclinical development in Dengue in USA Updated 28 Mar 2024 |
| 28 Mar 2024 | Phase Change - No development reported | No recent reports of development identified for preclinical development in Ebola-virus-infections in USA Updated 28 Mar 2024 |
| 28 Mar 2024 | Phase Change - No development reported | No recent reports of development identified for preclinical development in Influenza-A virus H3N2 subtype in USA Updated 28 Mar 2024 |
| 28 Mar 2024 | Phase Change - No development reported | No recent reports of development identified for preclinical development in Influenza-A virus H7N9 subtype in USA Updated 28 Mar 2024 |
| 28 Mar 2024 | Phase Change - No development reported | No recent reports of development identified for preclinical development in Influenza-A-virus-H1N1-subtype in USA Updated 28 Mar 2024 |
| 28 Mar 2024 | Phase Change - No development reported | No recent reports of development identified for preclinical development in Influenza-A-virus-H5N1-subtype in USA Updated 28 Mar 2024 |
| 28 Mar 2024 | Phase Change - No development reported | No recent reports of development identified for preclinical development in Influenza-B-virus-infections in USA Updated 28 Mar 2024 |
| 28 Mar 2024 | Phase Change - No development reported | No recent reports of development identified for preclinical development in Parainfluenza-virus-infections in USA Updated 28 Mar 2024 |
| 28 Mar 2024 | Phase Change - No development reported | No recent reports of development identified for preclinical development in Rhinovirus-infections in USA Updated 28 Mar 2024 |
| 25 Feb 2020 | Patent Information | Global Biolife has multiple patents pending for phenolic compounds in multiple countries before February 2020 [2] Updated 06 Mar 2020 |
| 25 Feb 2020 | Phase Change - Preclinical | Preclinical trials in COVID-2019-infections in USA (unspecified route) before February 2020 [1] Updated 06 Mar 2020 |
| 25 Feb 2020 | Phase Change - Preclinical | Preclinical trials in Dengue in USA (unspecified route) before February 2020 [1] Updated 06 Mar 2020 |
| 25 Feb 2020 | Phase Change - Preclinical | Preclinical trials in Ebola virus infections in USA (unspecified route) before February 2020 [1] Updated 06 Mar 2020 |
| 25 Feb 2020 | Phase Change - Preclinical | Preclinical trials in Influenza A virus H1N1 subtype in USA (unspecified route) before February 2020 [1] Updated 06 Mar 2020 |
| 25 Feb 2020 | Phase Change - Preclinical | Preclinical trials in Influenza A virus H3N2 subtype in USA (unspecified route) before February 2020 [1] Updated 06 Mar 2020 |
| 25 Feb 2020 | Phase Change - Preclinical | Preclinical trials in Influenza A virus H5N1 subtype in USA (unspecified route) before February 2020 [1] Updated 06 Mar 2020 |
| 25 Feb 2020 | Phase Change - Preclinical | Preclinical trials in Influenza A virus H7N9 subtype in USA (unspecified route) before February 2020 [1] Updated 06 Mar 2020 |
| 25 Feb 2020 | Phase Change - Preclinical | Preclinical trials in Influenza B virus infections in USA (unspecified route) before February 2020 [1] Updated 06 Mar 2020 |
| 25 Feb 2020 | Phase Change - Preclinical | Preclinical trials in Parainfluenza virus infections in USA (unspecified route) before February 2020 [1] Updated 06 Mar 2020 |
| 25 Feb 2020 | Phase Change - Preclinical | Preclinical trials in Rhinovirus infections in USA (unspecified route) before February 2020 [1] Updated 06 Mar 2020 |
| 13 Nov 2018 | Patent Information | Global Biolife has patent protection for phenolic compounds in USA [2] Updated 06 Mar 2020 |
References
-
GRDG Sciences Announces Successful Antiviral Testing of Equivir Preparations Underway for Coronavirus Testing.
Media Release -
Global Biolife INC-Patent. Internet-Doc 2020;.
Available from: URL: https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2017201042
Adis International Ltd. Part of Springer Science+Business Media
© Springer Nature Switzerland AG